Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Eunice S. Wang*, Ghayas C. Issa, Harry P. Erba, Jessica K. Altman, Pau Montesinos, Stephane DeBotton, Roland B. Walter, Kristen Pettit, Michael R. Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R. Baer, James M. Foran, Gary Schiller, Lionel Adès, Mael Heiblig, Celine Berthon, Pierre Peterlin, Eduardo Rodríguez-Arbolí, Olga SalameroMrinal M. Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M. Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S. Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T. Fathi

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry